Use of Immunohistochemical Markers (HNF-1β, Napsin A, ER, CTH, and ASS1) to Distinguish Endometrial Clear Cell Carcinoma From Its Morphologic Mimics Including Arias-Stella Reaction
暂无分享,去创建一个
S. Leung | D. Huntsman | C. Chow | B. Gilks | B. Tessier-Cloutier | L. Hoang | D. Cochrane | A. Cheng | J. Ji
[1] P. Ip,et al. Napsin A, Hepatocyte Nuclear Factor-1-Beta (HNF-1&bgr;), Estrogen and Progesterone Receptors Expression in Arias-Stella Reaction , 2019, The American journal of surgical pathology.
[2] C. Gilks,et al. Issues in the Differential Diagnosis of Uterine Low-grade Endometrioid Carcinoma, Including Mixed Endometrial Carcinomas: Recommendations from the International Society of Gynecological Pathologists , 2018, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[3] O. Fadare,et al. Endometrial Serous Carcinoma With Clear-Cell Change: Frequency and Immunohistochemical Analysis , 2018, International journal of surgical pathology.
[4] Nadeem Shafique Butt,et al. Infrequent Immunohistochemical Expression of Napsin A in Endometrial Carcinomas , 2017, Applied immunohistochemistry & molecular morphology : AIMM.
[5] D. Huntsman,et al. Clear cell and endometrioid carcinomas: are their differences attributable to distinct cells of origin? , 2017, The Journal of pathology.
[6] Juan Ye,et al. Cystathionine- γ-lyase promotes process of breast cancer in association with STAT3 signaling pathway , 2017, Oncotarget.
[7] G. Birdsong,et al. Recent Developments in Surgical Pathology of the Uterine Corpus. , 2017, Archives of pathology & laboratory medicine.
[8] Gregg B. Morin,et al. Quantitative Profiling of Single Formalin Fixed Tumour Sections: proteomics for translational research , 2016, Scientific Reports.
[9] Omar S. Gómez,et al. Cystathionine: A novel oncometabolite in human breast cancer. , 2016, Archives of Biochemistry and Biophysics.
[10] O. Fadare. Expression of Napsin A is common in Arias-Stella reaction. , 2016, Human pathology.
[11] J. Prat,et al. Mixed and Ambiguous Endometrial Carcinomas: A Heterogenous Group of Tumors With Different Clinicopathologic and Molecular Genetic Features , 2016, The American journal of surgical pathology.
[12] O. Fadare,et al. Arias-Stella Reaction in Progestin-Treated Endometrioid Adenocarcinoma , 2016, International journal of surgical pathology.
[13] M. Köbel,et al. Molecular Analysis of Mixed Endometrial Carcinomas Shows Clonality in Most Cases , 2015, The American journal of surgical pathology.
[14] Meenakshi Singh,et al. Endometrial Carcinoma: Role of Current and Emerging Biomarkers in Resolving Persistent Clinical Dilemmas. , 2016, American journal of clinical pathology.
[15] P. Dundr,et al. Expression, Epigenetic and Genetic Changes of HNF1B in Endometrial Lesions , 2016, Pathology and Oncology Research.
[16] E. Oliva,et al. Immunohistochemical Comparison of Ovarian and Uterine Endometrioid Carcinoma, Endometrioid Carcinoma With Clear Cell Change, and Clear Cell Carcinoma , 2015, The American journal of surgical pathology.
[17] M. Köbel,et al. Endometrial Carcinomas With Clear Cells: A Study of a Heterogeneous Group of Tumors Including Interobserver Variability, Mutation Analysis, and Immunohistochemistry With HNF-1&bgr; , 2015, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[18] Y. Nakatani,et al. Napsin A is frequently expressed in clear cell carcinoma of the ovary and endometrium. , 2015, Human pathology.
[19] Chengquan Zhao,et al. Comparative analysis of Napsin A, alpha-methylacyl-coenzyme A racemase (AMACR, P504S), and hepatocyte nuclear factor 1 beta as diagnostic markers of ovarian clear cell carcinoma: an immunohistochemical study of 279 ovarian tumours , 2015, Pathology.
[20] Insun Kim,et al. Should Endometrial Clear Cell Carcinoma be Classified as Type II Endometrial Carcinoma? , 2015, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[21] B. Karlan,et al. Differential expression of argininosuccinate synthetase in serous and non‐serous ovarian carcinomas , 2014, The journal of pathology. Clinical research.
[22] S. Toyokuni,et al. Napsin A is a specific marker for ovarian clear cell adenocarcinoma , 2015, Modern Pathology.
[23] Chao Zhao,et al. Wnt/β-catenin signaling induces the transcription of cystathionine-γ-lyase, a stimulator of tumor in colon cancer. , 2014, Cellular signalling.
[24] M. Yasuda. Immunohistochemical characterization of endometrial carcinomas: Endometrioid, serous and clear cell adenocarcinomas in association with genetic analysis , 2014, The journal of obstetrics and gynaecology research.
[25] H. Lee,et al. Napsin A is a useful marker for metastatic adenocarcinomas of pulmonary origin , 2014, Histopathology.
[26] C. Shao,et al. Hydrogen sulfide (H2S)/cystathionine γ-lyase (CSE) pathway contributes to the proliferation of hepatoma cells. , 2014, Mutation research.
[27] D. Huntsman,et al. Immunohistochemical characterization of prototypical endometrial clear cell carcinoma—diagnostic utility of HNF‐1β and oestrogen receptor , 2014, Histopathology.
[28] J. Hecht,et al. Frequent Expression of Napsin A in Clear Cell Carcinoma of the Endometrium: Potential Diagnostic Utility , 2014, The American journal of surgical pathology.
[29] S. Leung,et al. HNF-1&bgr; in Ovarian Carcinomas With Serous and Clear Cell Change , 2013, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[30] C Blake Gilks,et al. Poor Interobserver Reproducibility in the Diagnosis of High-grade Endometrial Carcinoma , 2013, The American journal of surgical pathology.
[31] J. Hecht,et al. Morphologic and other clinicopathologic features of endometrial clear cell carcinoma: a comprehensive analysis of 50 rigorously classified cases. , 2013, American journal of cancer research.
[32] O. Fadare,et al. Diagnostic Utility of Hepatocyte Nuclear Factor 1-Beta Immunoreactivity in Endometrial Carcinomas: Lack of Specificity For Endometrial Clear Cell Carcinoma , 2012, Applied immunohistochemistry & molecular morphology : AIMM.
[33] Y. Jeng,et al. Utility of hepatocyte nuclear factor‐1β as a diagnostic marker in ovarian carcinomas with clear cells , 2012, Histopathology.
[34] Dennis C. Sgroi,et al. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes , 2016 .
[35] Thomas Zeng,et al. Use of mutation profiles to refine the classification of endometrial carcinomas , 2012, The Journal of pathology.
[36] E. Pirog,et al. The Diagnosis of Endometrial Carcinomas With Clear Cells by Gynecologic Pathologists: An Assessment of Interobserver Variability and Associated Morphologic Features , 2012, The American journal of surgical pathology.
[37] S. Wiseman,et al. Loss of BAF250a (ARID1A) is frequent in high‐grade endometrial carcinomas , 2011, The Journal of pathology.
[38] A. Gadducci,et al. Clear cell carcinoma of the endometrium: a biological and clinical enigma. , 2010, Anticancer research.
[39] A. Olawaiye,et al. Management of women with clear cell endometrial cancer: a Society of Gynecologic Oncology (SGO) review. , 2009, Gynecologic oncology.
[40] H. Tsuda,et al. Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium. , 2007, Human pathology.
[41] D. Wheatley. Arginine deprivation and metabolomics: important aspects of intermediary metabolism in relation to the differential sensitivity of normal and tumour cells. , 2005, Seminars in cancer biology.
[42] R. Vang,et al. Immunohistochemical Staining for Ki-67 and p53 Helps Distinguish Endometrial Arias-Stella Reaction from High-Grade Carcinoma, Including Clear Cell Carcinoma , 2004, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[43] J. Arias-Stella. The Arias-Stella Reaction: Facts and Fancies Four Decades After , 2002, Advances in anatomic pathology.
[44] R. Kurman,et al. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. , 1998, Human pathology.
[45] P. Huettner,et al. Arias-Stella reaction in nonpregnant women: a clinicopathologic study of nine cases. , 1994, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[46] V. Gould,et al. Arias-Stella reaction with prominent nuclear pseudoinclusions simulating herpetic endometritis. , 1982, Diagnostic gynecology and obstetrics.
[47] W. Welch,et al. Precancerous lesions of the endometrium. , 1977, Human pathology.
[48] J. Azzopardi,et al. Synthetic progestogen-oestrogen therapy and uterine changes , 1967, Journal of clinical pathology.
[49] R. Fienberg,et al. THE ARIAS-STELLA REACTION: A NONSPECIFIC INVOLUTIONAL PHENOMENON IN INTRA- AS WELL AS EXTRAUTERINE PREGNANCY. , 1965, American journal of clinical pathology.
[50] J. Arias-Stella. Abnormal endometrial changes induced in the rat; the effects of chorionic hormone and estrogen. , 1955, A.M.A. archives of pathology.
[51] J. Arias-Stella. Atypical endometrial changes associated with the presence of chorionic tissue. , 1954, A.M.A. archives of pathology.